antibodi
profil
potenti
revolution
person
medicin
provid
import
inform
relat
autoimmun
selfprotein
exposur
infecti
agent
one
immunoassay
technolog
luciferas
immunoprecipit
system
lip
har
lightemit
recombin
protein
gener
robust
highqual
antibodi
data
often
span
larg
dynam
rang
detect
describ
gener
format
lip
discuss
studi
use
technolog
measur
autoantibodi
sever
human
autoimmun
diseas
includ
type
diabet
sj
ogren
syndrom
system
lupu
erythematosu
immunodefici
secondari
anticytokin
autoantibodi
also
describ
use
evalu
antibodi
singl
multipl
antigen
infecti
agent
diagnosi
pathogen
discoveri
obtain
individu
exposur
profil
divers
find
support
notion
lip
use
technolog
gener
antibodi
profil
person
diagnosi
monitor
human
health
translat
research
abbrevi
ard
acut
respiratori
distress
syndrom
dntm
dissemin
nontubercul
mycobacteri
ebv
epsteinbarr
viru
elisa
enzymelink
immunoassay
hcv
hepat
c
viru
hiv
human
immunodefici
viru
htlv
human
tlymphotrop
viru
il
ntibodi
key
compon
immun
system
abl
bind
great
specif
extrem
larg
varieti
target
molecul
addit
import
function
adapt
immun
respons
antibodi
test
repres
major
tool
diagnosi
mani
infecti
agent
includ
current
past
exposur
detect
antibodi
selfprotein
autoantibodi
also
import
diagnosi
varieti
autoimmun
diseas
autoimmun
diseas
autoantibodi
present
onset
clinic
symptom
certain
target
autoantibodi
play
direct
role
caus
pathogenesi
although
full
spectrum
diagnost
use
antibodi
current
known
gener
comprehens
antibodi
profil
like
repres
import
next
step
understand
human
health
review
describ
antibodi
profil
technolog
luciferas
immunoprecipit
system
lip
discuss
wide
rang
applic
type
inform
obtain
use
technolog
indepth
discuss
immunoassay
technolog
use
measur
antibodi
found
recent
review
clinic
inform
provid
quantifi
antibodi
long
recogn
common
immunoassay
technolog
western
blot
enzymelink
immunosorb
assay
elisa
use
measur
amount
antibodi
particular
target
number
drawback
includ
limit
abil
effici
detect
conform
epitop
limit
dynam
rang
detect
high
background
frequent
associ
use
crude
protein
prepar
bacteri
recombin
protein
contrast
fluidphas
radioimmunoprecipit
assay
use
radiolabel
antigen
overcom
mani
limit
method
choic
measur
autoantibodi
autoimmun
diseas
despit
use
radioimmunoprecipit
assay
requir
radioisotop
limit
widespread
applic
altern
radioimmunoprecipit
assay
measur
antibodi
fluidphas
lip
technolog
base
luciferasetag
antigen
produc
mammalian
cell
lip
technolog
gene
encod
luciferas
isol
soft
coral
renilla
reniformi
typic
use
report
lightproduc
enzym
highli
linear
output
span
order
magnitud
construct
renilla
luciferas
ruc
chimer
gene
involv
standard
molecular
techniqu
mammalian
express
vector
eg
antigen
interest
fuse
infram
ruc
varieti
recombin
protein
target
use
lip
includ
fulllength
protein
protein
variant
fragment
short
peptid
nonprotein
target
phospholipid
dna
rna
use
lip
initi
lip
plasmid
encod
lightemit
antigen
fusion
first
transfect
mammalian
cell
fig
antigen
directli
tag
luciferas
crude
extract
use
without
need
timeconsum
protein
purif
importantli
mani
crude
extract
contain
ructag
antigen
store
frozen
aliquot
thaw
use
later
time
antibodi
test
defin
amount
ructag
recombin
protein
base
light
unit
first
incub
serum
sampl
typic
hour
assay
ml
serum
use
potenti
allow
determin
made
ml
serum
plasma
first
incub
step
antibodi
serum
present
bind
target
antigen
fuse
ruc
fig
reaction
mixtur
transfer
addit
hour
filter
plate
contain
antibodi
captur
reagent
protein
ag
bead
secondari
immunoglobulinimmobil
bead
although
bead
bind
free
immunoglobulin
antibodi
bound
ructag
antigen
free
unbound
luciferasetag
antigen
remov
microtit
filter
plate
multipl
wash
step
next
rel
amount
antibodi
bound
ructag
antigen
determin
measur
light
produc
ad
coelenterazin
substrat
ruc
fig
note
varieti
lip
format
perform
collect
highli
quantit
antibodi
data
includ
singl
tube
assay
plate
rapid
test
array
even
microfluid
devic
time
requir
perform
lip
test
less
hour
typic
faster
elisa
western
blot
although
current
commerci
product
avail
specif
lip
test
lip
vector
use
gener
lightemit
protein
avail
request
dr
peter
burbelo
autoimmun
condit
autoimmun
diseas
quit
common
condit
associ
signific
morbid
mortal
cost
mani
autoimmun
diseas
genet
inform
offer
limit
diagnost
predict
clinic
valu
complex
diseas
caus
singl
genet
alter
rather
involv
multipl
weakli
associ
gene
polymorph
interact
variou
environment
factor
contrari
autoantibodi
detect
autoimmun
condit
repres
import
tool
person
care
provid
inform
diagnosi
monitor
even
diseas
predict
describ
applic
lip
measur
autoantibodi
wide
rang
autoimmun
studi
yield
improv
diagnost
perform
new
inform
tabl
type
diabet
autoimmun
diseas
involv
destruct
insulinproduc
pancreat
beta
cell
sever
differ
autoantibodi
identifi
includ
insulin
glutam
insulinomaassoci
insulinomaassoci
beta
zinc
although
radioimmunoprecipit
assay
rip
fluidphas
immunoassay
gold
standard
detect
autoantibodi
lip
repres
promis
nonradioact
altern
compar
studi
shown
lip
rip
similar
sensit
specif
detect
autoantibodi
sever
major
autoantigen
exampl
detect
autoantibodi
patient
lip
demonstr
sensit
specif
autoantibodi
valu
obtain
correl
well
radioimmunoprecipit
assay
studi
dynam
rang
detect
lip
assay
greater
radioimmunoprecipit
assay
span
light
unit
sever
investig
success
use
lip
nonradioact
altern
measur
autoantibodi
autoantibodi
rel
newli
identifi
autoantigen
pancreat
duoden
shown
lip
preval
patient
harbor
autoantibodi
multipl
autoantigen
lampasona
et
al
detect
high
level
robust
autoantibodi
lip
harmonin
villin
patient
autoimmun
condit
immunodysregul
polyendocrinopathi
enteropathi
xlink
syndrom
found
evid
autoantibodi
also
import
point
immunoassay
includ
elisa
protein
array
often
inadequ
detect
autoantibodi
autoimmun
condit
lack
diagnost
util
solidphas
assay
exemplifi
recent
studi
show
protein
array
technolog
unabl
detect
signific
autoantibodi
respons
major
known
autoantigen
detect
lip
serum
sampl
patient
acquir
autoantibodi
profil
multipl
autoantigen
target
highli
desir
studi
shown
number
differ
islet
autoantibodi
present
given
individu
greatest
predict
valu
determin
children
go
develop
diabet
addit
patient
also
show
evid
comorbid
autoimmun
condit
detect
presenc
autoantibodi
associ
condit
modular
natur
assay
abil
use
crude
extract
without
purif
lip
ideal
test
multipl
autoantigen
addit
assay
develop
time
gener
much
lesser
solidphas
immunoassay
use
nativ
recombin
protein
develop
differ
lightemit
protein
detector
lip
simpli
involv
clone
transfect
extract
gener
use
standard
format
without
optim
one
investig
autoantibodi
target
measur
patient
patient
show
high
frequenc
autoantibodi
approxim
patient
autoantibodi
respons
least
one
extrapancreat
target
includ
thyroid
peroxidas
associ
hashimoto
thyroid
transglutaminas
associ
celiac
diseas
gastric
adenosin
triphosphatas
associ
autoimmun
gastriti
although
clinic
data
cohort
avail
analysi
studi
demonstr
possibl
use
lip
identifi
patient
subgroup
differ
clinic
symptom
examin
potenti
genet
associ
addit
high
frequenc
autoantibodi
found
patient
autoantibodi
also
detect
sever
neurolog
diseas
includ
stiff
person
syndrom
ataxia
stiff
person
syndrom
lip
detect
highli
robust
level
autoantibodi
achiev
diagnost
accuraci
sensit
specif
anoth
studi
lip
also
use
screen
cohort
psychiatr
patient
autoantibodi
high
level
autoantibodi
detect
femal
patient
major
depress
disord
show
sign
psychomotor
slow
clinic
condit
character
slow
movement
extrem
increas
autoantibodi
also
highli
detect
cerebrospin
fluid
patient
autoantibodi
level
correl
time
clinic
sever
suggest
central
nervou
system
autoimmun
might
respons
psychomotor
impair
find
support
idea
uncov
unrecogn
autoimmun
pathogenesi
human
diseas
autoantibodi
profil
ogren
syndrom
ss
autoimmun
diseas
character
autoimmun
attack
salivari
lacrim
gland
lead
decreas
saliva
tear
product
respect
one
object
criterion
diagnosi
ss
involv
measur
autoantibodi
ssb
la
ssa
lip
show
sensit
detect
la
autoantibodi
compar
sensit
establish
elisa
small
cohort
patient
ss
healthi
control
ssa
lip
separ
detect
autoantibodi
show
similar
diagnost
perform
elisa
measur
togeth
measur
autoantibodi
target
also
reveal
patient
also
signific
autoantibodi
associ
autoimmun
condit
exampl
patient
ss
autoantibodi
thyroid
peroxidas
autoantigen
associ
hashimoto
thyroid
similarli
patient
ss
autoantibodi
gastric
adenosin
triphosphatas
aquaporin
respect
repres
potenti
autoimmun
attack
stomach
nervou
system
compar
standard
hourtest
format
rapid
lip
test
show
promis
detect
serum
autoantibodi
diagnosi
ss
highli
robust
lip
assay
use
noninvas
test
use
saliva
instead
serum
clinic
sampl
use
saliva
autoantibodi
show
sensit
specif
diagnosi
ss
correl
serum
level
autoantibodi
abil
examin
antibodi
saliva
addit
applic
noninvas
studi
humor
respons
infecti
agent
system
lupu
erythematosu
sle
repres
rel
common
autoimmun
diseas
character
inflamm
chronic
immun
attack
variou
cell
tissu
detect
autoantibodi
sle
critic
diagnosi
diseas
monitor
predict
diseas
onset
ching
et
al
use
lip
detect
autoantibodi
panel
autoantigen
reveal
patient
sle
either
cluster
cluster
ii
antibodi
phenotyp
patient
cluster
phenotyp
show
enrich
autoantibodi
sm
rnp
rnabind
protein
wherea
patient
cluster
ii
phenotyp
enrich
autoantibodi
la
exact
method
analyz
lip
autoantibodi
data
patient
sle
simpli
involv
compar
respons
sm
rnp
vs
la
contrast
previou
studi
base
elisa
immunoassay
result
identifi
similar
autoantibodi
cluster
sle
use
rel
complex
kmean
cluster
algorithm
overal
find
highlight
eas
antibodi
analysi
robust
highli
quantit
valu
gener
lip
technolog
anoth
uniqu
featur
lip
possibl
use
antigen
mixtur
achiev
high
diagnost
perform
singl
test
mixtur
format
base
fact
protein
ag
bead
use
assay
bind
mani
differ
immunoglobulin
present
serum
incub
multipl
lightemit
antigen
bound
immunoglobulin
interact
multipl
detector
yield
overal
signal
similar
perform
test
separ
fig
case
diagnosi
lupu
singl
lip
mixtur
test
incorpor
antigen
sm
rnp
la
combin
ml
serum
match
sensit
specif
perform
individu
lip
test
separ
approach
provid
inform
specif
target
protein
immunoreact
seroposit
sampl
need
addit
followup
test
individu
antigen
would
need
perform
nevertheless
lip
mixtur
approach
save
time
resourc
also
use
simplifi
diagnosi
sever
infecti
agent
besid
autoantibodi
biomark
pathogen
autoantibodi
interfer
normal
process
directli
caus
human
diseas
pathogen
autoantibodi
gener
cytokin
secret
molecul
play
critic
role
regul
immun
respons
infect
lip
detect
high
level
anticytokin
autoantibodi
sever
diseas
includ
certain
patient
acut
respiratori
distress
syndrom
sepsi
sle
opportunist
infect
secondari
anticytokin
autoantibodi
patient
thymoma
exhibit
opportunist
infect
mucocandidiasi
dissemin
varicellazost
viru
lip
identifi
multipl
anticytokin
autoantibodi
like
culprit
involv
pathogenesi
although
lip
detect
known
increas
level
antiinterferon
alfa
autoantibodi
high
level
autoantibodi
interleukin
il
correl
better
presenc
opportunist
infect
patient
level
autoantibodi
detect
lip
cytokin
also
match
function
assay
signal
transduc
activ
transcript
neutral
experi
lastli
studi
also
highlight
lip
use
autoantigen
discoveri
studi
systemat
lip
screen
differ
candid
cytokin
result
discoveri
patient
previous
undescrib
autoantibodi
b
cellactiv
factor
cytokin
abil
screen
mani
differ
antigen
parallel
lip
use
analyz
cohort
patient
dissemin
nontubercul
mycobacteri
dntm
infect
understand
full
spectrum
anticytokin
autoantibodi
patient
dntm
infect
sever
immunosuppress
harbor
infect
numer
rapid
slow
grow
mycobacteria
analyz
autoantibodi
cytokin
immun
target
approxim
patient
dntm
infect
demonstr
interferon
gamma
ifng
autoantibodi
routin
time
greater
level
found
control
level
ifng
autoantibodi
detect
lip
serum
sampl
patient
dntm
infect
also
track
abil
neutral
downstream
signal
activ
detect
vitro
assay
one
patient
dntm
infect
ifng
autoantibodi
show
high
level
antigranulocytemacrophag
colonystimul
factor
autoantibodi
remark
signific
autoantibodi
seroposit
detect
cytokin
result
suggest
lip
technolog
use
identifi
pathogen
autoantibodi
cytokin
potenti
extracellular
target
full
spectrum
human
diseas
show
autoantibodi
known
like
diseas
may
unrecogn
autoimmun
compon
two
diseas
fit
categori
acut
respiratori
distress
syndrom
sepsi
condit
character
intens
immun
activ
lead
organ
failur
lip
detect
evid
robust
autoantibodi
sever
autoantigen
includ
cytokin
known
autoantigen
also
demonstr
rapid
induct
autoantibodi
day
suggest
ongo
inflamm
may
mediat
break
toler
selfprotein
collect
result
present
highlight
possibl
use
lip
detect
new
biomark
mani
diseas
includ
condit
classic
thought
involv
autoimmun
respons
antibodi
test
repres
major
tool
diagnosi
mani
infecti
agent
provid
insight
current
past
exposur
even
respons
vaccin
liquidphas
immunoassay
radioimmunoprecipit
assay
gener
use
measur
antibodi
infecti
agent
requir
radioact
label
recent
develop
lip
liquidphas
immunoassay
use
interrog
antibodi
wide
rang
differ
infecti
agent
includ
fungal
filari
bacteri
viral
agent
subsequ
describ
studi
discuss
lip
provid
new
inform
detect
antibodi
infecti
agent
tabl
ii
one
key
advantag
lip
highli
robust
antibodi
level
often
seen
multipl
protein
given
infecti
agent
help
distinguish
infect
patient
uninfect
control
sever
infecti
agent
sidebysid
comparison
shown
improv
diagnost
potenti
lip
classic
elisa
test
exampl
lipss
show
greater
sensit
compar
elisa
sever
immunoassay
detect
strongyloid
stercorali
onchocerciasi
loa
loa
infect
agent
diagnost
perform
lip
compar
elisa
test
shown
addit
use
featur
exampl
lip
test
borrelia
burgdorferi
bacteri
caus
lyme
diseas
also
match
diagnost
perform
establish
lyme
elisa
test
use
exclud
major
role
lyme
diseas
pathogenesi
autism
lip
test
common
herpesviru
infect
varicellazost
viru
abl
distinguish
vaccin
unvaccin
subject
match
gold
standard
fluoresc
antibodi
membran
antigen
test
epsteinbarr
viru
ebv
herpesviru
lip
test
detect
antibodi
ebv
correl
antibodi
neutral
assay
could
use
measur
respons
ebv
vaccin
abil
use
crude
lysat
transfect
cell
without
protein
purif
also
make
lip
practic
approach
measur
antibodi
differ
protein
given
infecti
agent
includ
whole
proteom
human
immunodefici
viru
hiv
partial
proteom
human
tlymphotrop
viru
htlv
hepat
c
viru
hcv
ebv
approach
also
use
screen
identifi
new
antigen
protein
infecti
agent
exampl
screen
antigen
wuchereria
bancrofti
identifi
highli
inform
antigen
diagnosi
filari
infect
similarli
screen
protein
kaposiassoci
herpesviru
kshv
identifi
robust
antibodi
vcyclin
patient
kaposi
sarcoma
interestingli
antibodi
vcyclin
detect
sever
solidphas
format
includ
western
blot
protein
array
consist
better
detect
conform
antibodi
liquidphas
immunoassay
compar
solidphas
assay
lip
mixtur
assay
kshv
antigen
target
effici
detect
infect
match
sensit
specif
perform
separ
elisa
test
owe
abil
lip
detect
antibodi
multipl
antigen
differ
virus
uniqu
antibodi
profil
identifi
patient
subset
includ
patient
infect
ebv
kshv
hiv
exampl
patient
htlviassoci
myelopathi
debilit
neurolog
diseas
caus
viral
infect
show
high
level
antienvelop
antibodi
compar
asymptomat
infect
individu
patient
lymphoma
patient
chronic
activ
ebv
antiebv
antibodi
profil
show
greater
antibodi
level
sever
lytic
ebv
antigen
compar
healthi
control
consist
increas
ebv
replic
patient
patient
kshvassoci
diseas
rel
antibodi
level
lytic
vs
latent
viral
antigen
markedli
greater
multicentr
castlemen
diseas
compar
patient
kaposi
sarcoma
differ
antibodi
pattern
seen
patient
subgroup
like
reflect
alter
protein
express
andor
immun
recognit
infect
agent
lip
also
provid
simpl
biomark
studi
clinic
subset
patient
hiv
mendoza
et
al
analyz
cohort
elit
hiv
control
patient
show
exquisit
control
hiv
infect
found
novel
low
antibodi
respons
signatur
revers
transcriptas
proteas
integras
consist
possibl
patient
low
level
replic
hiv
viru
subsequ
hiv
studi
humor
respons
examin
lip
hiv
protein
patient
low
hiv
viral
load
includ
elit
control
antiretroviraltr
patient
berlin
patient
first
patient
cure
key
find
berlin
patient
undetect
antibodi
hiv
protein
still
weak
hivantibodi
respons
tat
revers
transcriptas
anoth
studi
patient
coinfect
hcvhiv
novel
hcv
antibodi
biomark
profil
identifi
lip
correl
respons
treatment
interferon
alfa
ribavirin
overal
result
hiv
hcv
suggest
quantit
antibodi
profil
gener
lip
could
use
monitor
therapi
loa
loa
improv
serolog
test
compar
elisa
l
loa
infect
develop
highperform
rapid
test
l
loa
antibodi
ebv
discov
uniqu
antibodi
profil
patient
chronic
activ
ebv
demonstr
ebv
antibodi
detect
lip
correl
neutral
antiebv
antibodi
hiv
evalu
antibodi
hiv
proteom
use
defin
recombin
protein
discov
uniqu
antibodi
signatur
subset
elit
hiv
control
obtain
evid
near
absenc
antihiv
antibodi
first
person
cure
berlin
patient
distinguish
patient
hiv
blood
donor
control
base
broad
antibodi
profil
multipl
common
infecti
agent
analyz
antibodi
full
proteom
discov
high
level
antienvelop
antibodi
patient
htlviassoci
myelopathytrop
spastic
paraparesi
compar
asymptomat
patient
associ
lymphoma
hcv
identifi
antibodi
profil
correl
respons
treatment
patient
infect
hcvhiv
screen
w
bancrofti
protein
antibodi
identifi
earli
specif
marker
infect
spite
identif
novel
infecti
agent
nucleic
acid
amplif
dna
sequenc
approach
import
point
full
spectrum
infecti
agent
impact
health
remain
larg
incomplet
detect
specif
antibodi
respons
provid
vivo
evid
infect
robust
antibodi
respons
obtain
lip
use
anoth
tool
pathogen
discoveri
exampl
numer
astrovirus
identifi
metagenom
sequenc
human
stool
vivo
relev
agent
unknown
lip
test
one
new
astrovirus
hmoastvc
reveal
signific
antibodi
capsid
viru
human
sever
anim
speci
includ
pig
rabbit
analysi
sampl
children
reveal
approxim
children
approxim
adult
show
antibodi
hmoastvc
find
support
incorpor
highqual
serolog
lip
data
acceler
discoveri
new
pathogen
obtain
nucleic
acid
discoveri
effort
lip
also
help
identifi
anim
reservoir
humanrel
virus
one
studi
lip
use
identifi
natur
reservoir
hcvlike
virus
nonprim
area
research
initi
start
kapoor
et
al
discov
first
nonprim
homolog
hcv
call
canin
hepativiru
dog
serolog
perform
time
develop
subsequ
lip
test
capsid
helicas
region
canin
hepaciviru
fail
detect
antibodi
canin
serum
sampl
suggest
infect
viru
may
rare
event
dog
howev
addit
test
varieti
anim
reveal
approxim
hors
show
robust
antibodi
respons
helicas
dna
analysi
seroposit
hors
identifi
new
genet
distinct
nonhuman
primat
hepatitislik
virus
equin
sampl
establish
hors
major
reservoir
hcvlike
virus
recent
lip
use
investig
anim
reservoir
middl
east
respiratori
syndrom
mer
viru
potenti
lethal
viral
infect
human
occur
saudi
arabia
although
serolog
evid
mer
infect
observ
sheep
goat
camel
identifi
sourc
mer
result
highlight
lip
use
discov
novel
pathogen
anim
caus
zoonot
infect
human
increas
evid
suggest
complic
interact
bodi
microbi
agent
even
exposur
mani
infecti
agent
caus
overt
diseas
may
influenc
human
health
one
import
opportun
person
health
profil
defin
individu
exposur
profil
multipl
infecti
agent
proof
concept
lip
use
measur
antibodi
common
infecti
agent
differ
chronic
diseas
patient
hiv
ifng
autoantibodi
ss
rather
focus
antibodi
respons
one
individu
infecti
agent
cumul
antibodi
data
model
princip
compon
analysi
patient
hiv
patient
high
level
autoantibodi
ifng
distinct
antibodi
profil
observ
compar
healthi
control
subject
moreov
notic
differ
profil
highlight
fact
diseas
perturb
differ
specif
immun
pathway
contrast
ss
cohort
reveal
inform
profil
suggest
infecti
agent
might
less
relev
diseas
basi
promis
find
like
incorpor
addit
infecti
agent
target
panel
might
make
approach
even
inform
final
abil
profil
mani
differ
infecti
agent
singl
format
present
power
tool
diagnosi
person
medicin
might
configur
novel
immun
readout
overal
immun
health
review
discuss
lip
liquidphas
immunoassay
provid
import
inform
diagnosi
monitor
insight
diseas
pathogenesi
mani
divers
studi
provid
platform
extens
interrog
antibodi
profil
human
diseas
four
major
attribut
make
lip
highli
desir
technolog
studi
antibodi
assay
requir
radioact
possibl
stabli
store
fusion
antigen
extract
facil
test
demand
high
signaltonois
ratio
wide
dynam
rang
antibodi
detect
lip
requir
small
amount
serum
hundr
target
could
theoret
profil
serum
obtain
sever
millilit
process
blood
besid
test
one
protein
time
lip
array
offer
altern
format
simultan
multipl
antibodi
differ
lightemit
protein
target
test
individu
well
plate
control
test
serum
sampl
proof
concept
lip
array
detect
highli
robust
immunoreact
multipl
protein
deriv
hcv
hiv
ebv
proteom
infect
subject
compar
uninfect
control
basi
result
lip
array
could
use
discoveri
tool
simultan
measur
antibodi
level
candid
target
protein
autoimmun
infecti
diseas
expect
come
year
antibodi
profil
gener
lipss
continu
provid
import
inform
relat
pathogenesi
diagnosi
one
strategi
predict
medicin
involv
monitor
antibodi
longitudin
time
mani
differ
target
along
line
conceiv
librari
known
autoantigen
target
use
lip
could
prove
suffici
broad
diagnosi
mani
common
autoimmun
disord
current
known
autoantibodi
present
year
clinic
onset
sever
autoimmun
condit
includ
sle
ss
possibl
lip
assay
along
clinic
inform
includ
associ
famili
member
presenc
risk
gene
could
effici
use
identifi
individu
high
risk
develop
condit
includ
cancer
agerel
neurolog
diseas
addit
approach
use
lip
serolog
profil
antibodi
multipl
infecti
agent
could
use
identifi
novel
agent
might
contribut
inflamm
impact
likelihood
develop
certain
diseas
importantli
antibodi
profil
might
use
earli
detect
therebi
identifi
patient
clinic
onset
may
allow
chang
lifestyl
treatment
option
might
delay
prevent
diseas
onset
progress
conflict
interest
author
read
journal
polici
disclosur
potenti
conflict
interest
one
author
pdb
patent
applic
submit
regard
use
luciferas
immunoprecipit
system
detect
antibodi
wucheria
bancrofti
lyme
diseas
author
potenti
conflict
interest
declar
author
also
read
journal
authorship
agreement
review
approv
manuscript
editori
support
use
prepar
manuscript
work
support
intramur
research
program
nation
institut
dental
craniofaci
research
nation
institut
health
